NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Alterome Therapeutics, Inc.
Boston Scientific Corporation
AstraZeneca
Boston Scientific Corporation
Pheon Therapeutics
Boehringer Ingelheim
Pheon Therapeutics
Auricula Biosciences Inc.
DualityBio Inc.
Inhibrx Biosciences, Inc
Exelixis
Tanabe Pharma America, Inc.
CRISPR Therapeutics
Massive Bio, Inc.
SillaJen, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Travera Inc
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Numab Therapeutics AG
HiberCell, Inc.
Boston Scientific Corporation
Intensity Therapeutics, Inc.
LEO Pharma
LEO Pharma
Sirtex Medical
Travera Inc
BeiGene
Imunon
Kyowa Kirin Co., Ltd.
Celon Pharma SA
Myeloid Therapeutics
Celgene
MedImmune LLC
Kineta Inc.
Cantargia AB
Shanghai Yunying Medical Technology
Amgen
Genocea Biosciences, Inc.
Eisai Inc.
Akamis Bio
Daiichi Sankyo
Symphogen A/S
Polaris Group
MultiVir, Inc.
Pfizer
Dynavax Technologies Corporation
Evolve Biologics